Enhancing prognostic evaluation in cardiac amyloidosis: PALS, GLS and functional tests beyond KCCQ
- 1Department of Medical Biotechnologies, Division of Cardiology, University of Siena
Abstract
Background: Cardiac amyloidosis (CA) often leads to reduced functional abilities, quality of life, and potential psychological repercussions. Several tests assess functional capacity, with the KCCQ score being the most widely used for heart failure symptoms, but it may overly rely on psychological factors. Left atrial (LA) strain indicates left ventricular (LV) diastolic function and filling pressure but doesn't correlate with KCCQ scores. The relationship between other tests and functional capacity or HRQoL (health-related quality of life) in CA remains unexplored.
Objective: This observational study aimed to assess the correlation between LA strain and LV global longitudinal strain (LVGLS) with functional tests. Furthermore, we aimed to examine their association with NT-proBNP levels and 6MWT in patients affected by CA, encompassing both AL and ATTR subtypes.
Methods: We enrolled patients with CA during their follow-up visits. They underwent clinical, echocardiographic, functional capacity and quality-of-life assessments, including the 6-minute walk test (6MWT) at baseline and after 3–6 months during follow-up visits, while subsequent clinical follow-up was used to ascertain the composite endpoint. The composite endpoint included all-cause mortality, hospitalization or emergency department visit for heart failure, and urgent cardiovascular visits for worsening heart failure symptoms. Deaths were further classified as cardiovascular or non-cardiovascular according to the predefined cause-of-death classification.
Results: In total, 67 patients diagnosed with CA (48 ATTRwt and 19 AL, average age 78 years, 21% female) were included. At baseline, patients had an LVEF of 53 ± 7%, a LVGLS of −13 ± 6% and mean PALS of 13 ± 7%. Global PALS demonstrated a positive correlation with DASI score ( p = 0.06) and 6MWT ( p = 0.004), and showed an inverse correlation with MLHFQ score ( p = 0.005) and NT-proBNP ( p = 0.003) while it was not correlated with KCCQ ( p = 0.21). GLS demonstrated a positive correlation with NT-proBNP ( p = 0.001), Minnesota score ( p = 0.01), DASI score ( p = 0.017). In contrast, the KCCQ did not correlate with NT-proBNP, PALS, 6MWT, or GLS. 42 patients (62.7%) experienced the composite endpoint. GLS was lower in the event group, PALS was lower, interventricular septal thickness (IVS) was larger, NT-proBNP was greater, and LAVi was higher. Our study showed that LVGLS, PALS, and apical sparing (RELAPS) were associated with the composite clinical endpoint, with LVGLS showing the numerically highest AUC among the evaluated parameters (AUC 0.704 (95% CI: 0.595–0.813) for LVGLS, 0.663 (95% CI: 0.549–0.777) for PALS, and 0.660 (95% CI: 0.545–0.775) for RELAPS).
Conclusions: LVGLS showed significant associations with functional status and quality-of-life measures and had the numerically highest AUC for the composite clinical endpoint among the evaluated parameters.
Related
- Comprehensive Cardiac Computed Tomography for Anatomical Assessment, Functional Analysis, and Myocardial Tissue Characterization in a Patient With Coronary Anomaly and Cardiac Amyloidosis
- Managing Cardiac Amyloidosis in a Rural Cardiology Practice: Bridging Gaps in Specialized Evaluation and Disease-Modifying Treatment
- Dual cardiac amyloidosis with AL cardiomyopathy and ATTR cardiomyopathy in systemic AL amyloidosis: Recommendation for a myocardial histology-based diagnosis
- Closing the diagnostic gap in transthyretin cardiac amyloidosis: red flags, modern imaging, and emerging therapies
- How to individualize device therapy in transthyretin cardiac amyloidosis: A dyssynchrony-based case report.
BibTeX
@article{pastore2026enhancing,
title = {{Enhancing prognostic evaluation in cardiac amyloidosis: PALS, GLS and functional tests beyond KCCQ}},
author = {Maria Concetta Pastore and Mariangela Vigna and Elisa Giacomin and Sara Rosi and Federica Marrese and Gian Luca Ragazzoni and Flavio D'Ascenzi and Giulia Elena Mandoli and Luna Cavigli and Matteo Cameli and Marta Focardi},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = nov,
doi = {10.3389/fcvm.2026.1927407},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1927407/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Enhancing prognostic evaluation in cardiac amyloidosis: PALS, GLS and functional tests beyond KCCQ
AU - Maria Concetta Pastore
AU - Mariangela Vigna
AU - Elisa Giacomin
AU - Sara Rosi
AU - Federica Marrese
AU - Gian Luca Ragazzoni
AU - Flavio D'Ascenzi
AU - Giulia Elena Mandoli
AU - Luna Cavigli
AU - Matteo Cameli
AU - Marta Focardi
PY - 2026
DA - 2026/11/04
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1927407
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1927407/full
AB - Background: Cardiac amyloidosis (CA) often leads to reduced functional abilities, quality of life, and potential psychological repercussions. Several tests assess functional capacity, with the KCCQ score being the most widely used for heart failure symptoms, but it may overly rely on psychological factors. Left atrial (LA) strain indicates left ventricular (LV) diastolic function and filling pressure but doesn't correlate with KCCQ scores. The relationship between other tests and functional capacity or HRQoL (health-related quality of life) in CA remains unexplored. Objective: This observational study aimed to assess the correlation between LA strain and LV global longitudinal strain (LVGLS) with functional tests. Furthermore, we aimed to examine their association with NT-proBNP levels and 6MWT in patients affected by CA, encompassing both AL and ATTR subtypes. Methods: We enrolled patients with CA during their follow-up visits. They underwent clinical, echocardiographic, functional capacity and quality-of-life assessments, including the 6-minute walk test (6MWT) at baseline and after 3–6 months during follow-up visits, while subsequent clinical follow-up was used to ascertain the composite endpoint. The composite endpoint included all-cause mortality, hospitalization or emergency department visit for heart failure, and urgent cardiovascular visits for worsening heart failure symptoms. Deaths were further classified as cardiovascular or non-cardiovascular according to the predefined cause-of-death classification. Results: In total, 67 patients diagnosed with CA (48 ATTRwt and 19 AL, average age 78 years, 21% female) were included. At baseline, patients had an LVEF of 53 ± 7%, a LVGLS of −13 ± 6% and mean PALS of 13 ± 7%. Global PALS demonstrated a positive correlation with DASI score ( p = 0.06) and 6MWT ( p = 0.004), and showed an inverse correlation with MLHFQ score ( p = 0.005) and NT-proBNP ( p = 0.003) while it was not correlated with KCCQ ( p = 0.21). GLS demonstrated a positive correlation with NT-proBNP ( p = 0.001), Minnesota score ( p = 0.01), DASI score ( p = 0.017). In contrast, the KCCQ did not correlate with NT-proBNP, PALS, 6MWT, or GLS. 42 patients (62.7%) experienced the composite endpoint. GLS was lower in the event group, PALS was lower, interventricular septal thickness (IVS) was larger, NT-proBNP was greater, and LAVi was higher. Our study showed that LVGLS, PALS, and apical sparing (RELAPS) were associated with the composite clinical endpoint, with LVGLS showing the numerically highest AUC among the evaluated parameters (AUC 0.704 (95% CI: 0.595–0.813) for LVGLS, 0.663 (95% CI: 0.549–0.777) for PALS, and 0.660 (95% CI: 0.545–0.775) for RELAPS). Conclusions: LVGLS showed significant associations with functional status and quality-of-life measures and had the numerically highest AUC for the composite clinical endpoint among the evaluated parameters.
SN - 2297-055X
ER -